Seres Therapeutics, Inc.MCRBNASDAQ
LOADING
|||
| Metric | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 |
|---|---|---|---|---|---|
| Revenue Growth | +0.00% | -100.00% | +0.00% | +0.00% | +0.00% |
| Gross Profit Growth | +0.00% | -100.00% | +0.00% | +0.00% | +0.00% |
| EBITDA Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Operating Income Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Net Income Growth | +0.00% | +0.00% | +0.00% | +0.00% | -90.76% |
| EPS Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| EPS Diluted Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Weighted Average Shares Growth | +18.99% | +33.84% | +19.14% | +15.42% | +14.76% |
| Weighted Average Shares Diluted Growth | +18.99% | +33.84% | +19.30% | +15.42% | +14.92% |
| Dividends per Share Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Operating Cash Flow Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Free Cash Flow Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Receivables Growth | -100.00% | +0.00% | -40.91% | -95.26% | +0.00% |
| Inventory Growth | -100.00% | -100.00% | -100.00% | -100.00% | +0.00% |
| Asset Growth | -51.39% | -61.01% | -51.89% | -55.30% | -19.73% |
| Book Value per Share Growth | +0.00% | +0.00% | +0.00% | +0.00% | +59.20% |
| Debt Growth | -55.90% | -53.90% | -58.19% | -58.88% | -8.93% |
| R&D Expense Growth | -34.56% | -52.17% | -39.36% | -18.14% | -100.00% |
| SG&A Expenses Growth | -34.59% | -27.69% | -20.45% | -21.52% | -25.44% |